X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Rigel will able to commercialize the Gavreto (pralsetinib), which is an FDA-approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Blueprint Medicines
Deal Size: $117.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 22, 2024
Details:
The collaboration aims to conduct a Phase 2 clinical trial to evaluate Rezlidhia (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma (HGG) harboring an IDH1 mutation.
Lead Product(s): Olutasidenib,Temozolomide
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CONNECT
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1 (IDH1) mutation.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1 (IDH1) mutation.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
R289 is a prodrug of R835, an IRAK1/4 dual inhibitor, which has been shown in preclinical studies to block inflammatory cytokine production in response to toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling.
Lead Product(s): R289
Therapeutic Area: Oncology Product Name: R289
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
Rezlidhia (olutasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Optime Care
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 13, 2022
Details:
REZLIDHIA (olutasidenib) is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
REZLIDHIA (olutasidenib) is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
FT-2102 (olutasidenib), is an oral, small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes,in patients with relapsed/refractory acute myeloid leukemia.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
